ResearcherUniversity of South CarolinaNo recent work listed

Anuhya Kommalapati

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0032-2619; OpenAlex author ID A5027090396. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper

Papers 2

Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0676-8 ↗
Contemporary Management of Localized Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers10010024 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Amit Mahipal · 2 shared papers, 2018–2019 · strength 0.20
- Paper Contemporary Management of Localized Resectable Pancreatic Cancer. DOI 10.3390/cancers10010024 ↗
- Paper Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreat… DOI 10.1007/s10637-018-0676-8 ↗
Domenico Coppola · 1 shared paper, 2019 · strength 0.10
- Paper Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreat… DOI 10.1007/s10637-018-0676-8 ↗
Heloisa Prado Soares · 1 shared paper, 2019 · strength 0.10
- Paper Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreat… DOI 10.1007/s10637-018-0676-8 ↗
Richard D. Kim · 1 shared paper, 2019 · strength 0.10
- Paper Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreat… DOI 10.1007/s10637-018-0676-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.